The ICR Conference 2017 and 2018 attracted more than 900 attendees and researchers from every field of cannabis expertise. The forum included researchers from universities, representatives from government agencies, and a host of industry experts. Presentations, panels, and posters covered the scientific, medical, industrial, legal, economic, and social elements of cannabis research.
Dr. Allyn Howlett, Ph.D. will deliver the Mechoulam Lecture at the ICR Conference 2019. Dr. Howlett was personally recommended by Dr. Raphael Mechoulam for this honor citing her pioneering work on the discovery of the first cannabinoid receptor. Futhermore Dr. Howlett is a Professor in the Department of Physiology and Pharmacology at Wake Forest School of Medicine in Winston-Salem, North Carolina. Dr. Howlett is a member of the Center for Research on Substance Use and Addiction at Wake Forest. Also the NIDA-funded P50 Center for the Neurobiology of Addiction Treatment.
She received a B.S. from Pennsylvania State University, and a Ph.D. from Rutgers State University – New Brunswick. After earning her Ph.D., she had a fellowship at the University of Virginia.
Dr. Howlett’s research investigates (endo) cannabinoid and cannabinoid receptors, CB1 and CB2, the G-protein coupled receptors. Her laboratory investigates the mechanisms by which cannabinoid drugs and endocannabinoid compounds stimulate the CB1 cannabinoid receptor to select intracellular signal transduction pathways. Cultured neuronal cells are used to define the types of G proteins that interact with the CB1 receptor, and investigate the necessary receptor domains.
Phosphorylation of the receptor is an important means to direct signaling through specific G proteins or other signaling proteins such as β-arrestins, and Cannabinoid Receptor Interacting Proteins (CRIP). These studies assess the potential for drugs to promote partnering with different G proteins and accessory proteins and thereby direct the selection of signal transduction pathways (e.g., via adenylyl cyclase inhibition, MAPK activation, Ca2+ regulation, and NO production). The importance to drug discovery is the promotion of therapeutically beneficial actions (e.g., analgesia) with diminished untoward side effects (e.g., sedation, cognitive dysfunction).
Dr. Howlett has received continuous NIH/NIDA research funding since 1980 and she has published more than 150 peer-reviewed research articles in her career .
Mahmoud A. ElSohly is a Research Professor at The National Center for Natural Products Research, and Professor of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi (UM) and is the Director of the National Institute on Drug Abuse (NIDA) Marijuana Project at UM. President and Laboratory Director of ElSohly Laboratories Incorporated, an analytical forensic drug testing and a product development laboratory.
Most noteworthy, Mahmoud A. ElSohly received his undergraduate and Masters from Cairo University, Cairo, Egypt and his Ph.D. in 1975 from the University of Pittsburgh, School of Pharmacy, Pittsburgh, PA. And has been with the University of Mississippi since 1975 and has been the Director of the NIDA Marijuana Project since 1981. Over 40 years’ experience working with the isolation of natural products (notably cannabis secondary metabolites), synthetic, analytical and forensic chemistry. He also has more than 30 patents and over 300 publications in these areas of science. Dr. ElSohly is also a member of American Society of Pharmacognosy, American Chemical Society, American Academy of Forensic Sciences, Society of Forensic Toxicologist, International Cannabinoids Research Society, International Association of Cannabinoid Medicines to name a few.
Some of his honors are: Alexander O. Gettler Award from the American Academy of Forensic Sciences (AAFS) Toxicology Section, (2016) for his work in Toxicology, IACM Special Award for his Major Contributions to the Re-introduction of Cannabis as a Medicine from the International Association for Cannabinoid Medicines (2015), The Lifetime Achievement Award from the International Cannabinoid Research Society (2013), The University of Mississippi’s Distinguished Research and Creative Achievement Award (2013), The University of Pittsburgh Legacy Laureate Award (2011), The University of Mississippi’s School of Pharmacy Researcher of the Year Award (2011), and The University of Pittsburg, School of Pharmacy Distinguished Alumnus Award (2002).
ICR Conference Information
ICR Conference 2019 is a multidisciplinary conference connecting cannabis researchers and professionals from across the U.S. and internationally. It attracts 400–500 attendees for a three-day exploration of new cannabis knowledge and innovations that improve lives and contribute to science, medicine, and society.
For the first time, ICR 2019 will feature a 2-day Research Vendor Expo with opportunities for research organizations to serve as a sponsor for the conference. Exhibiting at ICR 2019 offers you the opportunity to become a vital part of this emerging research field. Connect with medical professionals, university researchers, private industry, and public policy officials in need of laboratory services, laboratory instrumentation and equipment, data analysis software, and identify outlets for dissemination research results.
ICR Mission Statement
The Institute of Cannabis Research (ICR) generates new knowledge and understanding of cannabis and its derivatives through research and education. Translating research discoveries into innovative applications that improve lives and contribute to science, medicine, and society.
The Colorado State Legislature approved a $1.8 million budget for the ICR in state fiscal year 2019.
- Developing an ICR management and research infrastructure
- Conducting multi-disciplinary cannabis research with CSU-Pueblo faculty and students
- Hosting an international, multi-disciplinary cannabis research conference.
Women’s Cannabis Chamber of Commerce business courses